Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Envarsus XR

PharmaDeviceNews Envarsus XR

Veloxis Pharmaceuticals’ more than $46 million Envarsus XR kickback resolution brings pharmaceutical marketing practices, federal compliance oversight and the company’s five-year corporate integrity obligations into focus. Representative image.

Pharma & Biotech

What the $46m Veloxis Pharmaceuticals settlement means for Envarsus XR

by Pallavi Madhiraju
August 15, 2026
0 Comments

Veloxis Pharmaceuticals will pay over $46 million over Envarsus XR conduct. See why five years of compliance oversight could matter even more.

Read More

Latest news and features

Should people without diabetes wear continuous glucose monitors? What the evidence actually shows
Can a blood test find cancer relapse before a scan? What ctDNA MRD can and cannot tell clinicians
Why oral peptide medicines still fail even after GLP-1 drugs broke the injection barrier
Lutetium, actinium and the next isotope race: inside radiopharmaceutical cancer therapy
Why the next generation of antibody-drug conjugates is moving beyond simply finding new targets
Cubresa enters clinical neuroimaging as BrainPET receives first US 510(k) clearance.
Oncolytics says FDA opens a possible accelerated-approval route for pelareorep in RAS-mutant colorectal cancer
Sight Sciences wins TearCare label expansion after 345-patient SAHARA trial
Prizlon-cel reaches US clinical development as AbelZeta rebuilds its large B-cell lymphoma strategy.
Can permanent birth control move into the OB-GYN office? FemBloc gets a clearer FDA pathway.
LIB Therapeutics takes its $199-a-month PCSK9 strategy into an autoinjector for 2027
Could CABG stop depending on harvested veins? Vascudyne’s 18-month data strengthen the case.

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Kimbell Royalty (NYSE: KRP) closes $221m deal adding 2,347 boe/d
InPlay Oil (TSX: IPO) expands Belly River position as leverage rises with acquisition
Knights Group (AIM: KGH) targets 18% margin after £27m Moore Barlow deal
Aveng (JSE: AEG) returns to operating profit as headline loss narrows 95%
Welspun Corp’s Rs 17,200cr US pipe win pushes order book to record high

TAGS

clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immuno-oncology immunotherapy Inc. Johnson & Johnson medical devices oncology precision oncology rare disease U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.